Assessment of Enhanced Recovery After Surgery Implementation at Pediatric Surgery Practices in Mainland China

NCT ID: NCT05593861

Last Updated: 2022-10-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

66 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-01

Study Completion Date

2022-07-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Enhanced recovery after surgery (ERAS) is a new mode to optimize perioperative management, the core of which is to reduce perioperative physiological and psychological trauma and stress damage, and accelerate postoperative rehabilitation. ERAS has been gradually introduced in pediatric surgery in recent years, however, there are limited reports on its overall implementation. We aimed to determine the popularity of ERAS among pediatric populations in mainland China.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The application of ERAS in children with congenital biliary dilatation (CBD) was investigated. A total of 31 province-level administrative regions in mainland China were involved and each of them had at least one participating center. A questionnaire was designed to assess the baseline adherence of 17 recovery elements and chief pediatric surgeons at each center were invited to complete.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ERAS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

This investigation was conducted on chief surgeons at each center.

This investigation was conducted on chief surgeons at each center.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* chief pediatric surgeons at each center

Exclusion Criteria

* Incomplete questionnaire
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Weibing Tang

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Weibing Tang

Doctor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hua Xie, M.M.

Role: PRINCIPAL_INVESTIGATOR

Department of pediatric Surgery, Children's Hospital of Nanjing Medical University, Nanjing, China.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NJMU

Nanjing, Jiangsu, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Vacek J, Davis T, Many BT, Close S, Blake S, Hu YY, Holl JL, Johnson J, Strople J, Raval MV. A baseline assessment of enhanced recovery protocol implementation at pediatric surgery practices performing inflammatory bowel disease operations. J Pediatr Surg. 2020 Oct;55(10):1996-2006. doi: 10.1016/j.jpedsurg.2020.06.021. Epub 2020 Jun 27.

Reference Type BACKGROUND
PMID: 32713714 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NanjingCH13170

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.